• Email Us: [email protected]
  • Contact Us: +1 718 874 1545
  • Skip to main content
  • Skip to primary sidebar

Medical Market Report

  • Home
  • All Reports
  • About Us
  • Contact Us

CRISPR-Based HIV Gene Therapy Administered To First Human Patient

September 22, 2022 by Deborah Bloomfield

In a clinical trial, the first patient has received a single dose of a new human immunodeficiency virus (HIV) gene editing therapy, researchers at the Lewis Katz School of Medicine at Temple University and Excision BioTherapeutics, Inc have reported.

In a collaborative effort, the researchers are currently running a phase 1/2 clinical trial to evaluate the safety and efficacy of their therapy, called EBT-101, which is based on gene editing technology known as CRISPR. 

Advertisement

“Nearly 40 million people worldwide suffer from the effects of HIV, and more than 40 years after the discovery of HIV/AIDS, there still are no curative treatments,” said Professor Kamel Khalili, who helped lead the trial, in a statement. 

“EBT-101 can potentially address long-standing unmet needs of individuals living with HIV/AIDS by removing viral DNA from their cells, thereby eradicating infection.”

When HIV infects, it takes long-term hold and hides from the immune system in cells, compromising the patient’s immunity over time and eventually leading to the development of AIDS – the progressive failure of a patient’s immune system. There is currently no cure for HIV, but various treatments and medications can help manage the infection and slow or prevent the progression of the disease.

Advertisement



The therapy currently being trialed, which uses CRISPR gene editing to remove HIV viral DNA from infected cells, is a major step toward finding a therapeutic cure.

“We are well-positioned to collect key data that will enable our efforts to translate the success this approach has shown in animal models to human clinical trial participants,” Khalili added. “We look forward to investigating this hypothesis through the EBT-101 clinical program and are pleased that the EBT-101 Phase 1/2 trial is proceeding as planned.”

The first patient to receive a single dose of EBT-101 in the current trial is currently under medical supervision and will soon be assessed to see if there is any viral rebound and whether the single curative treatment worked as planned. This will be a deciding factor in whether or not the patient is able to stop their current antiretroviral therapy in the future.

Advertisement

“The official start of the Phase 1/2 clinical trials for EBT-101 brings us one extremely significant step closer to creating a potential cure for HIV/AIDS,” said Dr Amy J. Goldberg, Interim Dean of the Katz School of Medicine. “This amazing milestone speaks to the exceptional research acumen and scientific knowledge of Drs. Khalili and Burdo and their teams – outstanding members of the Temple family.”

For further details, you can view the clinical trial information at ClinicalTrials and follow its progress.

Deborah Bloomfield
Deborah Bloomfield

Related posts:

  1. ‘Hadestown’ marks return of Broadway musicals after 18-month shutdown
  2. Macron says French forces killed Islamic State leader in Sahara
  3. Italy’s Draghi to meet Greta Thunberg at Milan climate talks – source
  4. How “Diamond Dust” Sparkles In The Sky In Sub-Zero Temperatures

Source Link: CRISPR-Based HIV Gene Therapy Administered To First Human Patient

Filed Under: News

Primary Sidebar

  • Critically Endangered Shark Meat Is Being Sold In US Stores For As Little As $2.99
  • Infectious Mouth Bacteria Lurking In Artery Plaques Could Be Behind Some Heart Attacks
  • What Would You Reach If You Kept Digging Under Antarctica?
  • First Visible Time Crystals Ever Made Have Astonishing Complexity And Practical Potential
  • “Something Undeniably Special”: The Chi Cygnids, A New Five-Yearly Meteor Shower, Peak This Month
  • A 200-Meter-Tall Event We Didn’t See Sent Signals Through The Earth For Nine Whole Days
  • Why Are So Many Volcanoes Underwater?
  • In 1977, A Hybrid Was Born In A Zoo. What It Taught Us Could Save One Of The Planet’s Most Endangered Species
  • How To Park A Dangerous Asteroid So It Doesn’t Bite You Later
  • New Study Finds Evidence For What Every Parent Knows About Bluey
  • New Breakthrough Takes Plastic Garbage And Turns It Into Tool For Carbon Capture
  • NASA To Hold Press Conference About New Perseverance Rover Discovery Tomorrow
  • Strange Halos Have Formed Around Barrels Of Chemicals Dumped Off LA’s Coast Over 50 Years Ago
  • As We Grow Older, Our Music Taste Appears To Narrow To Fewer Songs
  • Stinky Seaweed Blob On Florida Beaches Thwarts Baby Sea Turtles’ Dash To The Ocean
  • NASA Is Set To Lock Up Four Volunteers For 378-Day Mars Simulation Study
  • For The First Time, A Vital Oceanic Upwelling Of Nutrient-Rich Water Failed To Emerge In 2025
  • One Of The Largest Crocs Ever “Terrorized Dinosaurs” With Teeth The Size Of Bananas
  • US Congress Is Holding Another UFO Hearing Today – Watch Live
  • Yes, Flying Snakes Do Exist – Sort Of
  • Business
  • Health
  • News
  • Science
  • Technology
  • +1 718 874 1545
  • +91 78878 22626
  • [email protected]
Office Address
Prudour Pvt. Ltd. 420 Lexington Avenue Suite 300 New York City, NY 10170.

Powered by Prudour Network

Copyrights © 2025 · Medical Market Report. All Rights Reserved.

Go to mobile version